default author photo

Joost S.P. Vermaat

Leiden University - Leiden University Medical Center (LUMC)

Albinusdreef 2

Leiden, South Holland 2333 ZA

Netherlands

SCHOLARLY PAPERS

2

DOWNLOADS

248

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial

Number of pages: 99 Posted: 11 Dec 2018
VU University Amsterdam - Department of Haematology, VU University Amsterdam, University of Groningen - Department of Hematology and Oncology, Erasmus University Rotterdam (EUR) - HOVON Data Center, Utrecht University - University Medical Center (Utrecht), Erasmus University Rotterdam (EUR) - Cancer Institute, KU Leuven - University Hospitals Leuven, University of Groningen, Leiden University - Leiden University Medical Center (LUMC), Leiden University - Leiden University Medical Center (LUMC), Oncology Center Isala, Canisius-Wilhelmina Ziekenhuis, Admiraal de Ruijter Hospital, University of Groningen - University Medical Center Groningen (UMCG), Radboud University Nijmegen - Radboud University Medical Center, Amsterdam UMC, Vrije Universiteit Amsterdam - Department of Radiology & Nuclear Medicine, VU University Amsterdam - Department of Hematology, VU University Amsterdam and University of Amsterdam, Academic Medical Center, Department of Hematology
Downloads 138 (530,816)
Citation 1

Abstract:

Loading...

Diffuse large B-cell lymphoma, MYC, BCL2, lenalidomide, interim PET scan, single hit, double hit, triple hit

2.

Selinexor in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): A Single-Arm Multinational Phase 2 Trial

Number of pages: 196 Posted: 11 Feb 2020
University of Liverpool, Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of Turin, NHS Foundation Trust - Addenbrooke's Hospital, Hackensack University - Hackensack University Medical Center, Leiden University - Leiden University Medical Center (LUMC), Centre Hospitalier Universitaire (CHU) de Bordeaux - Clinical Hematology Service, St. Vincent's Hospital Sydney, VU University Amsterdam - Department of Hematology, Dr. B. R. A. Institute Rotary Cancer Hospital AIIMS, Aix-Marseille University - Institut Paoli-Calmettes, Sorbonne University - University Hospitals Pitié Salpêtrière - Charles Foix, Tel Aviv University - Rabin Medical Center, Cleveland Clinic - Department of Hematology & Medical Oncology, Medical University of Vienna, Hospital Germans Trias y Pujol (ICO-IJC) - Hematology Department, State University of New York (SUNY), Stony Brook, University of Paris, Virgen del Rocio University, Kaposi MorCounty Teaching Hospital, Institute of Medical Sciences & SUM Hospital, Ghent University - Ghent University Hospital, National and Kapodistrian University of Athens, Instytut Hematologii i Transfuzjologii, Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Karyopharm Therapeutics, Inc., Catholic University of Louvain (UCL) - Cliniques Universitaires Saint-Luc and Hospital Universitario La Paz
Downloads 110 (640,165)

Abstract:

Loading...

Selinexor, SADAL trial, Relapsed/Refractory, Diffuse Large B-cell Lymphoma